Efficacy of Botulinum Toxin-A for Treating Idiopathic Detrusor Overactivity: Results From a Single Center, Randomized, Double-Blind, Placebo Controlled Trial
- 30 June 2007
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Urology
- Vol. 177 (6), 2231-2236
- https://doi.org/10.1016/j.juro.2007.01.130
Abstract
We evaluated the use of botulinum toxin-A in treating patients with idiopathic detrusor overactivity refractory to anticholinergics. This double-blind, placebo controlled trial randomized participants to intradetrusor injections of 200 U botulinum toxin-A (16 patients) or placebo (18 patients). The primary outcome measure was change in maximum cystometric capacity. Secondary outcome measures included changes in overactive bladder symptoms, post-void residual, maximum detrusor pressure during filling cystometry and reflex detrusor volume. Quality of life was assessed using the Incontinence Impact Questionnaire short form 7 and Urogenital Distress Inventory short form 6. Followup occurred at 4 and 12 weeks after injection, at which point the study was unblinded. Further followup in the botulinum toxin-A group occurred at 24 weeks. Significant increases in maximum cystometric capacity were observed at 4 weeks (difference 144.69 ml, 95% CI 100.95 to 215.75, p <0.0001) and 12 weeks (difference 95.71 ml, 95% CI 47.47 to 172.45, p = 0.001) in patients treated with botulinum toxin-A compared to placebo. Botulinum toxin-A reduced frequency (p <0.001, p = 0.003) and urgency urinary incontinence (p = 0.03, p = 0.008) episodes at 4 and 12 weeks, respectively. Urgency was reduced at 4 weeks (p = 0.005) in the botulinum toxin-A group. In patients receiving botulinum toxin-A, post-void residual increased at 4 weeks (p = 0.024) but became insignificant by 12 weeks (p = 0.406). Of these patients 6 required intermittent self-catheterization. Significant improvements in quality of life were observed following botulinum toxin-A. The extension study suggests that the beneficial effects of botulinum toxin-A are maintained for at least 24 weeks. Botulinum toxin-A at 200 U is safe and effective for idiopathic detrusor overactivity and the beneficial effects persist for at least 24 weeks.Keywords
This publication has 20 references indexed in Scilit:
- Experience With 100 Cases Treated With Botulinum-A Toxin Injections in the Detrusor Muscle for Idiopathic Overactive Bladder Syndrome Refractory to AnticholinergicsJournal of Urology, 2006
- A prospective study to evaluate the safety, tolerability, efficacy and durability of response of intravesical injection of botulinum toxin type A into detrusor muscle in patients with refractory idiopathic detrusor overactivityBJU International, 2005
- A COMPARISON BETWEEN THE RESPONSE OF PATIENTS WITH IDIOPATHIC DETRUSOR OVERACTIVITY AND NEUROGENIC DETRUSOR OVERACTIVITY TO THE FIRST INTRADETRUSOR INJECTION OF BOTULINUM-A TOXINJournal of Urology, 2005
- Clinical effects of suburothelial injection of botulinum A toxin on patients with nonneurogenic detrusor overactivity refractory to anticholinergicsUrology, 2005
- BOTULINUM TOXIN TYPE A IS A SAFE AND EFFECTIVE TREATMENT FOR NEUROGENIC URINARY INCONTINENCE: RESULTS OF A SINGLE TREATMENT, RANDOMIZED, PLACEBO CONTROLLED 6-MONTH STUDYJournal of Urology, 2005
- Botulinum toxin for the treatment of lower urinary tract symptoms: A reviewNeurourology and Urodynamics, 2004
- THE EFFECT OF BOTULINUM-A TOXIN ON PATIENTS WITH SEVERE URGE URINARY INCONTINENCEJournal of Urology, 2004
- European Experience of 200 Cases Treated with Botulinum-A Toxin Injections into the Detrusor Muscle for Urinary Incontinence due to Neurogenic Detrusor OveractivityEuropean Urology, 2004
- The standardisation of terminology of lower urinary tract function: Report from the standardisation sub‐committee of the International Continence SocietyNeurourology and Urodynamics, 2002
- BOTULINUM-A TOXIN FOR TREATING DETRUSOR HYPERREFLEXIA IN SPINAL CORD INJURED PATIENTS: A NEW ALTERNATIVE TO ANTICHOLINERGIC DRUGS? PRELIMINARY RESULTSJournal of Urology, 2000